GSK lung cancer drug shows 61% response rate in early global trial
GSK PLC reported that its experimental lung cancer drug, risvutatug rezetecan, showed a 61% response rate in an early-stage global trial at the higher dose tested. The company is using the higher dose in its ongoing phase III study and has seen manageable safety profiles. GSK acquired rights to the drug outside certain regions and is evaluating it for multiple cancer indications.
How this was made
The 30-second read
Why it matters
The data supports advancing the higher dose into Phase III, potentially increasing GSK's pipeline value.
Market read
First disclosure of strong early‑stage efficacy for a GSK lung‑cancer candidate, likely to influence investor sentiment.
What to watch
Trial size is small (18 evaluable patients at high dose); results may not scale.
Background
GSK is expanding its oncology portfolio with antibody‑drug conjugates targeting B7‑H3 across solid tumours.
Ticker impact
GSK reported 61% confirmed response rate for its lung cancer drug Risvutatug Rezetcane in an early‑stage global trial.
likely upside as market prices in the strong response rate
61% response is a material efficacy signal; safety profile acceptable for early phase, prompting optimism for Phase III.
Market effects
May boost sentiment for oncology biotech and antibody‑drug conjugates.
European pharma stocks could see modest gains.
Potentially relevant for global cancer‑therapy pipelines.
Counterpoint
Safety concerns with higher dose (42% serious adverse events) could temper enthusiasm.
Key entities
- companyGSK PLC
British pharmaceutical group reporting the trial results.
- companyHansoh Pharma
Original rights holder for the drug outside mainland China.
